Skip to main content

4 Result(s)

within Michael. B. Atkins Remove this filter Internal Medicine Remove this filter Pathology Remove this filter

and

  1. No Access

    Article

    Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy

    The availability of approved agents with distinct mechanisms of action (immunotherapy, vascular endothelial growth factor pathway, and mTOR inhibitors) has complicated treatment decisions for patients with adv...

    Michael B. Atkins in Medical Oncology (2009)

  2. No Access

    Article

    Kidney cancer: The cytokine working group experience (1986–2001)

    The Cytokine Working Group (CWG) was initially established in 1986 as the Extramural IL-2/LAK Working Group. With funding from the National Cancer Institute (NCI), the CWG was mandated to confirming data regar...

    Janice Dutcher M.D., Michael B. Atkins, Kim Margolin, Geoff Weiss… in Medical Oncology (2001)

  3. No Access

    Article

    Kidney cancer: The cytokine working group experience (1986–2001)

    The Cytokine Working Group (CWG) was initially established in 1986 as the Extramural IL-2/LAK Working Group. With funding from the National Cancer Institute (NCI), the CWG was mandated to confirming data regar...

    Michael B. Atkins, Janice Dutcher M.D., Geoff Weiss, Kim Margolin… in Medical Oncology (2001)

  4. No Access

    Article

    Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/α-interferon

    The inflammatory tumor lymphocytic infiltrates and spontaneous tumor regressions seen in patients with metastatic malignant melanomas suggest a cellular immune involvement. Enhancement of such responses has be...

    R Katherine Alpaugh PhD, Margaret von Mehren, Irma Palazzo… in Medical Oncology (1998)